B Adam Williams, P Michelle Fitzsimmons, Lavinia M Lewis, James Tornos, Luke Kimmel, Jane M True, Pamela J Siwik, Martina Ryall, Kilian Mullett
{"title":"The 100 Days Mission: a perspective on accelerating vaccine manufacturing for future pandemics.","authors":"B Adam Williams, P Michelle Fitzsimmons, Lavinia M Lewis, James Tornos, Luke Kimmel, Jane M True, Pamela J Siwik, Martina Ryall, Kilian Mullett","doi":"10.1186/s44263-026-00262-1","DOIUrl":null,"url":null,"abstract":"<p><p>The \"100 Days Mission\" aims to compress the timeline for delivering safe and effective vaccines in response to future pandemics. Here, we present insights from Pfizer leaders involved in the COVID-19 vaccine effort on key enablers for rapid large-scale manufacture of pandemic vaccines to achieve this ambitious goal. For pharmaceutical companies, these enablers include robust governance models, secure supply chains, innovative production strategies, and maintained \"warm\" manufacturing capacity. Additionally, we examine the crucial role of government support through regulatory harmonization, enhanced global surveillance, and improved logistics. By addressing these critical factors, the global community can better prepare for rapid vaccine manufacturing in response to future pandemic threats.</p>","PeriodicalId":519903,"journal":{"name":"BMC global and public health","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13003682/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC global and public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s44263-026-00262-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The "100 Days Mission" aims to compress the timeline for delivering safe and effective vaccines in response to future pandemics. Here, we present insights from Pfizer leaders involved in the COVID-19 vaccine effort on key enablers for rapid large-scale manufacture of pandemic vaccines to achieve this ambitious goal. For pharmaceutical companies, these enablers include robust governance models, secure supply chains, innovative production strategies, and maintained "warm" manufacturing capacity. Additionally, we examine the crucial role of government support through regulatory harmonization, enhanced global surveillance, and improved logistics. By addressing these critical factors, the global community can better prepare for rapid vaccine manufacturing in response to future pandemic threats.